Cardiac Tissue Engineering Market Size, Share & Trends by Material (Scaffold, Stem cells), Product (Heart Valve, Vascular Grafts), Applications (MI,Congenital Heart Disease), End-User (Hospitals & Clinics, Academics & Research Institutes) - Global Forecast to 2029
The global cardiac tissue engineering market is projected to reach USD 1,333.6 Million by 2029 from USD 621.2 Million in 2024, at a CAGR of 16.5% from 2024 to 2029. The growth of the market is driven Technological advancement in 3d bioprinting. The market also benefits from the up surge in prevalence of cardiovascular diseases across the globe. However, high cost associated with treating cardiovascular diseases by cardiac tissue engineering process, is impacting the growth of the market. Moreover, the stringent regulatory policies in the field of cardiac tissue engineering are a major factor restraining the market growth.
“Hydrogel based scaffolds segment to witness the significant growth during the forecast period.”
Based on material, the segment is divided into stem cells, and scaffolds. The scaffolds segment is further divided into synthetic scaffolds and biological scaffolds. The biological scaffolds are further segmented into collagen-based scaffolds and hydrogel-based scaffolds. In 2023, among these two biological scaffolds, the hydrogel-based scaffolds accounts for the significant share in cardiac tissue engineering market. This is due to their versatile properties that closely mimic natural tissue characteristics. Hydrogels are composed of highly hydrated networks, like the extracellular matrix, which promotes cell attachment, proliferation, and differentiation critical for tissue regeneration. Their mechanical properties can be tailored across a wide range to match those of specific tissues, enhancing compatibility and integration within the body. This tunability allows for the design of scaffolds with optimal porosity, biodegradability, and permeability, facilitating nutrient and oxygen diffusion essential for cell survival and tissue development. Moreover, hydrogels can be engineered to deliver bioactive molecules and growth factors in a controlled manner, further supporting tissue regeneration processes. Compared to collagen-based scaffolds, which also offer biological compatibility but have more limited mechanical tunability, hydrogels provide a superior platform for creating complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications. These advantages position hydrogel-based scaffolds as the preferred choice, driving their dominance in the biological scaffold segment of the scaffold market.
The segment is separated into scaffolds and stem cells based on the type of material. The material used on scaffolds is subdivided into two categories: biological scaffolds and synthetic scaffolds. Collagen- and hydrogel-based scaffolds are two further categories into which the biological scaffolds are divided. By 2023, the hydrogel-based biological scaffolds will have a larger market share in cardiac tissue engineering than the other two biological scaffolds combined. This is because of its adaptable qualities, which closely resemble those of natural tissue. Similar to the extracellular matrix, hydrogels are made of highly hydrated networks that support cell adhesion, proliferation, and differentiation—all of which are essential for tissue regeneration. Their ability to modify their mechanical characteristics to a large degree in order to match the characteristics of particular tissues improves their compatibility and integration with the body. dominance in the scaffold market's biological scaffold sector. Because of its tunability, scaffolds with the ideal porosity, biodegradability, and permeability may be designed, enabling the flow of nutrients and oxygen—both of which are necessary for tissue formation and cell survival. Hydrogels can also be designed to supply growth factors and bioactive compounds in a regulated way, which will aid in the processes involved in tissue regeneration. For the creation of complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications, hydrogels offer a superior platform than collagen-based scaffolds, which likewise offer biological compatibility but have less mechanical tunability. Because of these benefits, hydrogel-based scaffolds are positioned as the best option and dominate the market for biological scaffolds.
“Congenital heart disease treatment segment accounted for the significant share in the cardiac tissue engineering market during the forecast period.”
Based on application, the cardiac tissue engineering market is segmented into myocardial infarction, heart valve repair/replacement, congenital heart disease treatment and others. Among these in 2023, the congenital heart disease treatment accounted for significant share. This is attributed to the rising prevalence and critical medical needs associated with congenital heart defects globally. For instance, in Australia, approximately 65,000 individuals live with congenital heart disease, with around 5,900 cases diagnosed annually as the principal cause. This condition also accounts for 79 infant deaths annually, highlighting its severe impact on public health. Similarly, in the United States, nearly 40,000 infants are born with congenital heart defects each year, underscoring the substantial patient population requiring advanced treatment options. Cardiac tissue engineering offers promising solutions for congenital heart defects by providing tailored approaches to repair or replace defective heart tissues. These innovations are crucial in addressing the specific anatomical and physiological challenges presented by congenital heart diseases, which often require personalized and durable interventions from early infancy throughout adulthood. The increasing incidence of congenital heart defects globally drives demand for innovative therapies that can improve patient outcomes and quality of life, thereby bolstering the congenital heart disease segment's prominence in the cardiac tissue engineering market.
The cardiac tissue engineering market is divided into segments based on application, comprising treatment for congenital heart disease, myocardial infarction, and heart valve repair/replacement. Treatment for congenital cardiac disease accounted for a sizable portion of these in 2023. This is explained by the increased global prevalence of congenital cardiac abnormalities and the urgent medical needs they provide. For example, congenital heart disease affects about 65,000 people in Australia, with 5,900 new instances being diagnosed as the primary cause each year. Its devastating influence on public health is further evidenced by the 79 newborn fatalities that are attributed to this illness each year. Comparably, over 40,000 babies in the US are born with congenital cardiac abnormalities every year, highlighting the sizeable patient population in need of cutting-edge care. Cardiac tissue engineering provides customized methods for replacing or repairing damaged cardiac tissues, which presents promising remedies for congenital heart abnormalities. These advancements are essential for tackling the unique anatomical and physiological problems associated with congenital cardiac disorders, which frequently call for customized and long-lasting therapies from early childhood into adulthood. The need for novel treatments that can enhance patient outcomes and quality of life is being driven by the rising incidence of congenital heart problems worldwide. This is expected to increase the importance of the congenital heart disease segment in the cardiac tissue engineering market.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the cardiac tissue engineering market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period attributed to increase in strategic collaborations and robust research initiatives. In June 2023, the establishment of the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), involving patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank, underscored a concerted effort across nine health systems in Asia to enhance heart health and mitigate cardiovascular disease (CVD) impacts. Moreover, the presence of esteemed research institutions such as the Heart Research Institute, dedicated to advancing cardiovascular disease pathophysiology and pioneering tissue engineering solutions, enhances the region's capability to innovate in cardiac health technologies. With such collaborative frameworks and research capabilities, the Asia Pacific region is accelerating in scientific advancements for market growth in cardiac tissue engineering, promising significant opportunities for stakeholders in the sector.
.
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five main geographical regions into which the cardiac tissue engineering market is divided in the report. Due to a rise in strategic partnerships and active research projects, the APAC market is anticipated to grow at the fastest rate over the forecast period. The Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) was founded in June 2023 and represents a coordinated effort across nine Asian health systems to improve heart health and lessen the effects of cardiovascular disease (CVD). Participants in the alliance include patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank. Furthermore, the region's capacity to innovate in heart health technologies is further enhanced by the existence of prestigious research organizations like the Heart Research Institute, which is committed to studying the pathophysiology of cardiovascular illness and developing innovative tissue engineering treatments. The Asia Pacific area is experiencing a notable surge in scientific developments for cardiac tissue engineering market growth, thanks to the presence of collaborative frameworks and research capacities. This presents substantial prospects for industry stakeholders.
Breakdown of supply-side primary interviews, by company type, designation, and region:
This report studies the cardiac tissue engineering market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total cardiac tissue engineering market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
“Hydrogel based scaffolds segment to witness the significant growth during the forecast period.”
Based on material, the segment is divided into stem cells, and scaffolds. The scaffolds segment is further divided into synthetic scaffolds and biological scaffolds. The biological scaffolds are further segmented into collagen-based scaffolds and hydrogel-based scaffolds. In 2023, among these two biological scaffolds, the hydrogel-based scaffolds accounts for the significant share in cardiac tissue engineering market. This is due to their versatile properties that closely mimic natural tissue characteristics. Hydrogels are composed of highly hydrated networks, like the extracellular matrix, which promotes cell attachment, proliferation, and differentiation critical for tissue regeneration. Their mechanical properties can be tailored across a wide range to match those of specific tissues, enhancing compatibility and integration within the body. This tunability allows for the design of scaffolds with optimal porosity, biodegradability, and permeability, facilitating nutrient and oxygen diffusion essential for cell survival and tissue development. Moreover, hydrogels can be engineered to deliver bioactive molecules and growth factors in a controlled manner, further supporting tissue regeneration processes. Compared to collagen-based scaffolds, which also offer biological compatibility but have more limited mechanical tunability, hydrogels provide a superior platform for creating complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications. These advantages position hydrogel-based scaffolds as the preferred choice, driving their dominance in the biological scaffold segment of the scaffold market.
The segment is separated into scaffolds and stem cells based on the type of material. The material used on scaffolds is subdivided into two categories: biological scaffolds and synthetic scaffolds. Collagen- and hydrogel-based scaffolds are two further categories into which the biological scaffolds are divided. By 2023, the hydrogel-based biological scaffolds will have a larger market share in cardiac tissue engineering than the other two biological scaffolds combined. This is because of its adaptable qualities, which closely resemble those of natural tissue. Similar to the extracellular matrix, hydrogels are made of highly hydrated networks that support cell adhesion, proliferation, and differentiation—all of which are essential for tissue regeneration. Their ability to modify their mechanical characteristics to a large degree in order to match the characteristics of particular tissues improves their compatibility and integration with the body. dominance in the scaffold market's biological scaffold sector. Because of its tunability, scaffolds with the ideal porosity, biodegradability, and permeability may be designed, enabling the flow of nutrients and oxygen—both of which are necessary for tissue formation and cell survival. Hydrogels can also be designed to supply growth factors and bioactive compounds in a regulated way, which will aid in the processes involved in tissue regeneration. For the creation of complex tissue constructs in cardiac tissue engineering and other regenerative medicine applications, hydrogels offer a superior platform than collagen-based scaffolds, which likewise offer biological compatibility but have less mechanical tunability. Because of these benefits, hydrogel-based scaffolds are positioned as the best option and dominate the market for biological scaffolds.
“Congenital heart disease treatment segment accounted for the significant share in the cardiac tissue engineering market during the forecast period.”
Based on application, the cardiac tissue engineering market is segmented into myocardial infarction, heart valve repair/replacement, congenital heart disease treatment and others. Among these in 2023, the congenital heart disease treatment accounted for significant share. This is attributed to the rising prevalence and critical medical needs associated with congenital heart defects globally. For instance, in Australia, approximately 65,000 individuals live with congenital heart disease, with around 5,900 cases diagnosed annually as the principal cause. This condition also accounts for 79 infant deaths annually, highlighting its severe impact on public health. Similarly, in the United States, nearly 40,000 infants are born with congenital heart defects each year, underscoring the substantial patient population requiring advanced treatment options. Cardiac tissue engineering offers promising solutions for congenital heart defects by providing tailored approaches to repair or replace defective heart tissues. These innovations are crucial in addressing the specific anatomical and physiological challenges presented by congenital heart diseases, which often require personalized and durable interventions from early infancy throughout adulthood. The increasing incidence of congenital heart defects globally drives demand for innovative therapies that can improve patient outcomes and quality of life, thereby bolstering the congenital heart disease segment's prominence in the cardiac tissue engineering market.
The cardiac tissue engineering market is divided into segments based on application, comprising treatment for congenital heart disease, myocardial infarction, and heart valve repair/replacement. Treatment for congenital cardiac disease accounted for a sizable portion of these in 2023. This is explained by the increased global prevalence of congenital cardiac abnormalities and the urgent medical needs they provide. For example, congenital heart disease affects about 65,000 people in Australia, with 5,900 new instances being diagnosed as the primary cause each year. Its devastating influence on public health is further evidenced by the 79 newborn fatalities that are attributed to this illness each year. Comparably, over 40,000 babies in the US are born with congenital cardiac abnormalities every year, highlighting the sizeable patient population in need of cutting-edge care. Cardiac tissue engineering provides customized methods for replacing or repairing damaged cardiac tissues, which presents promising remedies for congenital heart abnormalities. These advancements are essential for tackling the unique anatomical and physiological problems associated with congenital cardiac disorders, which frequently call for customized and long-lasting therapies from early childhood into adulthood. The need for novel treatments that can enhance patient outcomes and quality of life is being driven by the rising incidence of congenital heart problems worldwide. This is expected to increase the importance of the congenital heart disease segment in the cardiac tissue engineering market.
“APAC is estimated to register the highest CAGR during the forecast period.”
In this report, the cardiac tissue engineering market is segmented into five major regional segments, namely, North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The market in APAC is projected to register the highest growth rate during the forecast period attributed to increase in strategic collaborations and robust research initiatives. In June 2023, the establishment of the Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance), involving patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank, underscored a concerted effort across nine health systems in Asia to enhance heart health and mitigate cardiovascular disease (CVD) impacts. Moreover, the presence of esteemed research institutions such as the Heart Research Institute, dedicated to advancing cardiovascular disease pathophysiology and pioneering tissue engineering solutions, enhances the region's capability to innovate in cardiac health technologies. With such collaborative frameworks and research capabilities, the Asia Pacific region is accelerating in scientific advancements for market growth in cardiac tissue engineering, promising significant opportunities for stakeholders in the sector.
.
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the five main geographical regions into which the cardiac tissue engineering market is divided in the report. Due to a rise in strategic partnerships and active research projects, the APAC market is anticipated to grow at the fastest rate over the forecast period. The Asia-Pacific Cardiovascular Disease Alliance (APAC CVD Alliance) was founded in June 2023 and represents a coordinated effort across nine Asian health systems to improve heart health and lessen the effects of cardiovascular disease (CVD). Participants in the alliance include patient organizations, allied health professionals, academia, corporate partners, and a global health think-tank. Furthermore, the region's capacity to innovate in heart health technologies is further enhanced by the existence of prestigious research organizations like the Heart Research Institute, which is committed to studying the pathophysiology of cardiovascular illness and developing innovative tissue engineering treatments. The Asia Pacific area is experiencing a notable surge in scientific developments for cardiac tissue engineering market growth, thanks to the presence of collaborative frameworks and research capacities. This presents substantial prospects for industry stakeholders.
Breakdown of supply-side primary interviews, by company type, designation, and region:
- By Company Type: Tier 1 (20%), Tier 2 (45%), and Tier 3 (35%)
- By Designation: C-level (30%), Director-level (20%), and Others (50%)
- By Region: North America (35%), Europe (24%), Asia Pacific (25%), RoW (16%)
- Terumo corporation (Japan)
- Artivion, Inc. (US)
- Baxter international, Inc. (US)
- Teijin Limited (Japan)
- Medtronic Plc. (Ireland)
- Boston Scientific Corporation (US)
- Abbott Laboratories (US)
- Merck KGaA (Germany)
- Elutia. (US)
- W. L. Gore & Associates, Inc. (US)
- Meril Lifesciences Pvt.Ltd (India)
- Fujifilm Holdings Corporation (Japan)
- Vascudyne, Inc. (US)
- BICO - THE BIO CONVERGENCE COMPANY (Sweden)
- ReproCELL, Inc. (US)
- PromoCell GmBH (Germany)
- Axol Bioscience Ltd. (UK)
- BPS Bioscience, Inc. (US)
- Cell Application, Inc. (US)
- Viscofan DE GmBH (Germany)
This report studies the cardiac tissue engineering market based on product, procedure, technology, application, end user and region. The report also analyses factors (such as drivers, restraints, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total cardiac tissue engineering market. The report forecasts the revenue of the market segments with respect to five major regions.
Reasons to Buy the Report
This report also includes.
- Analysis of key drivers (rising prevalence of cardiovascular diseases, increase in support from major market players and government bodies, Increased demand for regenerative medicine, the advancement of 3D bioprinting),restraints (High cost of treatment, Complex regulatory process), challenges (Safety concerns and complexity of biomaterials, Limited awareness and scarcity of skilled professionals), opportunities (Technological advancement in cardiac tissue engineering, The ability of biomaterials to enhance the functionality and integration of cardiac tissues offers significant opportunities, Increase in research of stems cells to treat cardiovascular diseases) contributing the growth of the cardiac tissue engineering market.
- Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the cardiac tissue engineering market.
- Market Development: Comprehensive information on the lucrative emerging markets, product, procedure, technology, application, end-user and region.
- Market Diversification: Exhaustive information about the growing geographies, recent developments, investments in the cardiac tissue engineering market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global cardiac tissue engineering market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MATERIAL DEFINITION
1.2.2 PRODUCT DEFINITION
1.2.3 APPLICATION DEFINITION
1.2.4 END USER DEFINITION
1.2.5 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.2 RESEARCH METHODOLOGY DESIGN
2.2.1 SECONDARY RESEARCH
2.2.2 KEY DATA FROM SECONDARY SOURCES
2.2.3 PRIMARY DATA
2.2.4 KEY DATA FROM PRIMARY SOURCES
2.2.5 KEY INDUSTRY INSIGHTS
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 MARKET SHARE ESTIMATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 RESEARCH LIMITATIONS
2.8.1 METHODOLOGY-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CARDIAC TISSUE ENGINEERING MARKET OVERVIEW
4.2 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION
4.3 REGIONAL SNAPSHOT OF CARDIAC TISSUE ENGINEERING MARKET (2023)
4.4 GEOGRAPHIC MIX: CARDIAC TISSUE ENGINEERING MARKET,
2024–2029 (USD MILLION)
4.5 CARDIAC TISSUE ENGINEERING MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of cardiovascular diseases
5.2.1.2 Increase in support from major market players and government bodies
5.2.1.3 Increased demand for regenerative medicine
5.2.1.4 Advancements in 3D bioprinting
5.2.2 RESTRAINTS
5.2.2.1 High cost of treatment
5.2.2.2 Complex regulatory process
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements in cardiac tissue engineering
5.2.3.2 Enhanced functionality and integration of cardiac tissues using biomaterials
5.2.3.3 Increase in stem cell research to treat cardiovascular diseases
5.2.4 CHALLENGES
5.2.4.1 Safety concerns and complexity of biomaterials
5.2.4.2 Limited awareness and availability of skilled professionals
5.3 INDUSTRY TRENDS
5.3.1 DEVELOPMENT OF BIOCOMPATIBLE AND BIODEGRADABLE MATERIALS
5.3.2 INTEGRATION OF MICROFLUIDICS AND ELECTRICAL STIMULATION FOR IMPROVED CELL FUNCTION AND TISSUE MATURATION
5.3.3 EXPANSION OF CARDIAC TISSUE ENGINEERING APPLICATIONS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.2 STEM CELL TECHNOLOGY
5.4.3 3D BIOPRINTING
5.4.4 BIOREACTORS
5.4.5 COMPLEMENTARY TECHNOLOGY
5.4.6 GENE EDITING
5.4.7 ELECTROSPINNING
5.4.8 MICROFLUIDICS
5.4.9 ADJACENT TECHNOLOGIES
5.4.9.1 Biosensors
5.4.10 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
5.4.11 NANOTECHNOLOGY
5.5 PIPELINE ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF SUPPLIERS
5.7.4 BARGAINING POWER OF BUYERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.8.2 BUYING CRITERIA
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY ANALYSIS
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 PATENT ANALYSIS
5.10.1 PATENT PUBLICATION TRENDS FOR CARDIAC TISSUE ENGINEERING MARKET
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.11.2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2021 (USD MILLION)
5.11.3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2021 (USD MILLION)
5.12 PRICING ANALYSIS
5.13 KEY CONFERENCES AND EVENTS, 2024–2025
5.14 UNMET NEEDS IN CARDIAC TISSUE ENGINEERING MARKET
5.15 END USER EXPECTATIONS IN CARDIAC TISSUE ENGINEERING MARKET
5.16 AI INTEGRATION IN CARDIAC TISSUE ENGINEERING MARKET
5.17 ECOSYSTEM ANALYSIS
5.18 CASE STUDIES
5.19 SUPPLY CHAIN ANALYSIS
5.20 CARDIAC TISSUE ENGINEERING MARKET: INVESTMENT AND FUNDING SCENARIO
5.21 ADJACENT MARKET ANALYSIS
5.21.1 TISSUE ENGINEERING MARKET
6 CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL
6.1 INTRODUCTION
6.2 STEM CELLS
6.2.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
6.3 SCAFFOLDS
6.3.1 SYNTHETIC SCAFFOLDS
6.3.1.1 Advancements in fabrication techniques to drive market
6.3.2 BIOLOGICAL SCAFFOLDS
6.3.3 COLLAGEN-BASED SCAFFOLDS
6.3.3.1 Biocompatibility of material – key driver
6.3.3.2 Hydrogel-based scaffolds
6.3.3.2.1 Low mechanical strength to restrain segment growth
7 CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT
7.1 INTRODUCTION
7.2 VASCULAR GRAFTS
7.2.1 INCREASE IN PREVALENCE OF CORONARY ARTERY DISEASE TO DRIVE MARKET
7.3 CARDIAC PATCHES
7.3.1 INCREASE IN CLINICAL TRIALS FOR CARDIAC PATCHES TO BOOST MARKET
7.4 HEART VALVES
7.4.1 INCREASE IN PREVALENCE OF VALVE REGURGITATION TO DRIVE MARKET
8 CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 MYOCARDIAL INFARCTION
8.2.1 IMPROVED STRUCTURAL INTEGRATION TO DRIVE MARKET GROWTH
8.3 HEART VALVE REPAIR/REPLACEMENT
8.3.1 INCREASE IN INCIDENCE OF AORTIC STENOSIS TO DRIVE MARKET
8.4 CONGENITAL HEART DISEASE
8.4.1 SIGNIFICANT INVESTMENT BY KEY MARKET PLAYERS TO DRIVE MARKET
8.5 OTHER APPLICATIONS
9 CARDIAC TISSUE ENGINEERING MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & CLINICS
9.2.1 ADVANCED INFRASTRUCTURE AND ACCESS TO CLINICAL TRIALS – KEY DRIVERS
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 AVAILABILITY OF FUNDING FOR RESEARCH – KEY DRIVER
9.4 OTHER END USERS
10 CARDIAC TISSUE ENGINEERING MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Increasing government grants for research to drive market
10.2.3 CANADA
10.2.3.1 Availability of funding for research on regenerative medicine to fuel market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 UK
10.3.2.1 Fastest-growing market for cardiac tissue engineering in Europe
10.3.3 GERMANY
10.3.3.1 Rising prevalence of cardiovascular diseases – key driver
10.3.4 FRANCE
10.3.4.1 Increasing focus on regenerative medicine to boost market
10.3.5 ITALY
10.3.5.1 Insufficient research funding to restrain growth of market
10.3.6 SPAIN
10.3.6.1 Increase in R&D investment to drive market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 JAPAN
10.4.2.1 Increasing aging population to drive market growth
10.4.3 CHINA
10.4.3.1 Major cardiac tissue engineering market in Asia Pacific
10.4.4 INDIA
10.4.4.1 Increasing government initiatives for clinical trials in stem cell research to boost market
10.4.5 AUSTRALIA
10.4.5.1 Growing government support to fuel market
10.4.6 SOUTH KOREA
10.4.6.1 Advancements in technology and strong government support to drive market growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Increase in prevalence of congenital heart disease to drive market
10.5.3 MEXICO
10.5.3.1 Rapidly growing geriatric population – key driver
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 EXPANDING NETWORK OF ADVANCED HEALTHCARE FACILITIES TO SUPPORT MARKET GROWTH
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.3 GCC COUNTRIES
10.6.3.1 Increased inclination toward novel therapies – key driver
10.6.4 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 REVENUE SHARE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 VALUATION AND FINANCIAL METRICS OF HEALTHCARE SERVICE VENDORS
11.6 COMPANY EVALUATION MATRIX, KEY PLAYERS (2023)
11.6.1 STARS
11.6.2 EMERGING LEADERS
11.6.3 PERVASIVE PLAYERS
11.6.4 PARTICIPANTS
11.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.6.5.1 Company footprint
11.6.5.2 Region footprint
11.6.5.3 Application footprint
11.6.5.4 Product footprint
11.6.5.5 Material footprint
11.6.5.6 End user footprint
11.7 COMPANY EVALUATION MATRIX, STARTUPS/SMES (2023)
11.7.1 PROGRESSIVE COMPANIES
11.7.2 RESPONSIVE COMPANIES
11.7.3 DYNAMIC COMPANIES
11.7.4 STARTING BLOCKS
11.7.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7.5.1 Detailed list of key startups/smes
11.7.5.2 Competitive benchmarking of key startups/SMEs
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES
11.8.2 DEALS
11.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 TERUMO CORPORATION
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 MnM view
12.1.1.3.1 Right to win
12.1.1.3.2 Strategic choices
12.1.1.3.3 Weaknesses & competitive threats
12.1.2 ARTIVION, INC.
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 BAXTER INTERNATIONAL, INC.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 TEIJIN LIMITED
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 MnM view
12.1.4.3.1 Right to win
12.1.4.3.2 Strategic choices
12.1.4.3.3 Weaknesses & competitive threats
12.1.5 MEDTRONIC PLC
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 BOSTON SCIENTIFIC CORPORATION
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 ABBOTT LABORATORIES
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.8 MERCK KGAA
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.9 FUJIFILM HOLDINGS CORPORATION
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 BICO - THE BIO CONVERGENCE COMPANY
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.11 ELUTIA
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.12 W. L. GORE AND ASSOCIATES, INC.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.13 MERIL LIFESCIENCES PVT. LTD.
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.14 VASCUDYNE, INC.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.15 REPROCELL, INC.
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.2 OTHER PLAYERS
12.2.1 AXOL BIOSCIENCE LTD.
12.2.2 BPS BIOSCIENCE, INC.
12.2.3 TAKARA BIO, INC.
12.2.4 XELTIS
12.2.5 VISCOFAN DE GMBH
12.2.6 CELL APPLICATION, INC
12.2.7 PROMOCELL GMBH
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
TABLE 1 CURRENCY CONVERSION RATES
TABLE 2 US: LEADING CAUSES OF DEATHS, 2021–2022
TABLE 3 CARDIAC TISSUE ENGINEERING MARKET: R&D PIPELINE
TABLE 4 CARDIAC TISSUE ENGINEERING MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 5 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
CARDIAC TISSUE ENGINEERING PRODUCTS
TABLE 6 KEY BUYING CRITERIA FOR CARDIAC TISSUE ENGINEERING PRODUCTS
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 12 CARDIAC TISSUE ENGINEERING MARKET: LIST OF PATENTS, 2014–2024
TABLE 13 AVERAGE SELLING PRICE OF CARDIAC TISSUE ENGINEERING PRODUCTS (USD)
TABLE 14 AVERAGE SELLING PRICE OF KEY CARDIAC TISSUE ENGINEERING PRODUCTS,
BY REGION, 2023 (USD)
TABLE 15 CARDIAC TISSUE ENGINEERING MARKET: KEY CONFERENCES
AND EVENTS, 2024–2025
TABLE 16 CARDIAC TISSUE ENGINEERING MARKET: UNMET NEEDS
TABLE 17 CARDIAC TISSUE ENGINEERING MARKET: END USER EXPECTATIONS
TABLE 18 CARDIAC TISSUE ENGINEERING MARKET: AI INTEGRATION
TABLE 19 CARDIAC TISSUE ENGINEERING MARKET: ECOSYSTEM ANALYSIS
TABLE 20 CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 1
TABLE 21 CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 2
TABLE 22 CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 3
TABLE 23 CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 24 CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 25 KEY PROVIDERS OF STEM CELLS
TABLE 26 STEM CELLS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 27 STEM CELLS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 28 KEY PROVIDERS OF SCAFFOLDS
TABLE 29 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY TYPE,
2021–2023 (USD MILLION)
TABLE 30 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY TYPE,
2024–2029 (USD MILLION)
TABLE 31 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 32 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 33 SYNTHETIC SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 34 SYNTHETIC SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 35 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY TYPE, 2021–2023 (USD MILLION)
TABLE 36 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY TYPE, 2024–2029 (USD MILLION)
TABLE 37 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 38 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 39 COLLAGEN-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 40 COLLAGEN-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 41 HYDROGEL-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 42 HYDROGEL-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 43 CARDIAC TISSUE ENGINEERING MARKET, PIPELINE ANALYSIS
TABLE 44 CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 45 CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 46 VASCULAR GRAFTS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 47 VASCULAR GRAFTS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 48 CARDIAC PATCHES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 49 CARDIAC PATCHES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 50 HEART VALVES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 51 HEART VALVES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 52 CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 53 CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 54 MYOCARDIAL INFARCTION: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 55 MYOCARDIAL INFARCTION: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 56 HEART VALVE REPAIR/REPLACEMENT: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 57 HEART VALVE REPAIR/REPLACEMENT: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 58 CONGENITAL HEART DISEASE: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 59 CONGENITAL HEART DISEASE: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 60 OTHER APPLICATIONS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 61 OTHER APPLICATIONS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 62 CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)E
TABLE 63 CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 64 HOSPITALS & CLINICS: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2021–2023 (USD MILLION)
TABLE 65 HOSPITALS & CLINICS: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2024–2029 (USD MILLION)
TABLE 66 ACADEMIC & RESEARCH INSTITUTES: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2021–2023 (USD MILLION)
TABLE 67 ACADEMIC & RESEARCH INSTITUTES: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2024–2029 (USD MILLION)
TABLE 68 OTHER END USERS: CARDIAC TISSUE ENGINEERING MARKET, BY REGION,
2021–2023 (USD MILLION)
TABLE 69 OTHER END USERS: CARDIAC TISSUE ENGINEERING MARKET, BY REGION,
2024–2029 (USD MILLION)
TABLE 70 CARDIAC TISSUE ENGINEERING MARKET, BY REGION, 2021–2023 (USD MILLION)
TABLE 71 CARDIAC TISSUE ENGINEERING MARKET, BY REGION, 2024–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 73 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 75 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 77 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 79 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 80 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 81 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 83 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 85 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 86 US: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 87 US: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 88 US: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 89 US: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 90 US: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 91 US: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 92 US: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 93 US: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 94 US: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 95 US: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 96 US: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 97 US: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 98 CANADA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 99 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 100 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 101 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 102 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 103 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 104 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 105 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 106 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 107 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 108 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 109 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 110 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 111 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 112 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 113 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 114 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 115 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 116 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 117 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 118 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 119 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 120 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 121 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 122 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 123 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 124 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 125 UK: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 126 UK: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 127 UK: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 128 UK: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 129 UK: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 130 UK: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 131 UK: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 132 UK: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 133 UK: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 134 UK: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 135 UK: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 136 UK: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 137 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 138 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 139 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 140 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 141 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 142 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 143 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 144 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 145 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 146 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 147 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 148 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 149 FRANCE: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 150 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 151 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 152 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 153 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 154 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 155 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 156 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 157 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 158 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 159 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 160 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 161 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 162 ITALY: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 163 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 164 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 165 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 166 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 167 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 168 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 169 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 170 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 171 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 172 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 173 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 174 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 175 SPAIN: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 176 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 177 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 178 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 179 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 180 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 181 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 182 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 183 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 184 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 185 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 186 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 187 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 188 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 189 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 190 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 191 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 192 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 193 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 194 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 195 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 196 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 197 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 198 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 199 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 200 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 201 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 202 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 203 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 205 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 207 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 208 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 209 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 210 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 211 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 212 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 213 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 214 JAPAN: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 215 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 216 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 217 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 218 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 219 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 220 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 221 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 222 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 223 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 224 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 225 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 226 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 227 CHINA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 228 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 229 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 230 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 231 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 232 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 233 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 234 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 235 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 236 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 237 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 238 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 239 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 240 INDIA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 241 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 242 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 243 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 244 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 245 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL TYPE,
2021–2023 (USD MILLION)
TABLE 246 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL TYPE,
2024–2029 (USD MILLION)
TABLE 247 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 248 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 249 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 250 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 251 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 252 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 253 AUSTRALIA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 254 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 255 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 256 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 257 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 258 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 259 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 260 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 261 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 262 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 263 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 264 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 265 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 266 SOUTH KOREA: KEY MACROINDICATORS FOR CARDIAC
TISSUE ENGINEERING MARKET
TABLE 267 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 268 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 269 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 270 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 271 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 272 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 273 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 274 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 275 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 276 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 277 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 278 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 279 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 280 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 281 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 282 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 283 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 284 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 285 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 286 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 287 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 288 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 289 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2021–2023 (USD MILLION)
TABLE 290 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2024–2029 (USD MILLION)
TABLE 291 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 292 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 293 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 294 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 295 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 296 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 297 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 298 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 299 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 300 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 301 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 302 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 303 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 304 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 305 BRAZIL: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 306 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 307 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 308 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 309 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 310 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 311 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 312 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 313 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 314 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION ,
2021–2023 (USD MILLION)
TABLE 315 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 316 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 317 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 318 MEXICO: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 319 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 320 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 321 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 322 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 323 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 324 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 325 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 326 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 327 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 328 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 329 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 330 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 331 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 332 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 333 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 334 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 335 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 336 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 337 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 338 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 339 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 340 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 341 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2021–2023 (USD MILLION)
TABLE 342 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2024–2029 (USD MILLION)
TABLE 343 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY, 2021–2023 (USD MILLION)
TABLE 344 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
TABLE 345 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 346 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 347 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 348 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 349 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 350 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 351 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 352 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 353 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 354 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 355 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2021–2023 (USD MILLION)
TABLE 356 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2024–2029 (USD MILLION)
TABLE 357 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 358 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 359 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 360 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 361 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 362 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 363 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 364 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 365 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 366 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 367 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 368 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 369 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 370 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 371 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 372 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 373 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 374 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 375 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 376 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 377 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 378 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 379 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2021–2023 (USD MILLION)
TABLE 380 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2024–2029 (USD MILLION)
TABLE 381 OVERVIEW OF STRATEGIES DEPLOYED BY CARDIAC TISSUE ENGINEERING
MARKET PLAYERS
TABLE 382 CARDIAC TISSUE ENGINEERING MARKET: DEGREE OF COMPETITION
TABLE 383 CARDIAC TISSUE ENGINEERING MARKET: REGION FOOTPRINT
TABLE 384 CARDIAC TISSUE ENGINEERING MARKET: APPLICATION FOOTPRINT
TABLE 385 CARDIAC TISSUE ENGINEERING MARKET: PRODUCT FOOTPRINT
TABLE 386 CARDIAC TISSUE ENGINEERING MARKET: MATERIAL FOOTPRINT
TABLE 387 CARDIAC TISSUE ENGINEERING: END USER FOOTPRINT
TABLE 388 CARDIAC TISSUE ENGINEERING MARKET: KEY STARTUPS/SMES
TABLE 389 CARDIAC TISSUE ENGINEERING MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS
TABLE 390 CARDIAC TISSUE ENGINEERING MARKET: PRODUCT LAUNCHES,
JANUARY 2020–JUNE 2023
TABLE 391 CARDIAC TISSUE ENGINEERING MARKET: DEALS, JANUARY 2020–JUNE 2024
TABLE 392 TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 393 TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 394 ARTIVION, INC.: COMPANY OVERVIEW
TABLE 395 ARTIVION, INC.: PRODUCTS OFFERED
TABLE 396 ARTIVION, INC.: DEALS, JANUARY 2020–JUNE 2024
TABLE 397 BAXTER INTERNATIONAL, INC: COMPANY OVERVIEW
TABLE 398 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED
TABLE 399 BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2020–JUNE 2024
TABLE 400 TEIJIN LIMITED: COMPANY OVERVIEW
TABLE 401 TEIJIN LIMITED: PRODUCTS OFFERED
TABLE 402 MEDTRONIC PLC: COMPANY OVERVIEW
TABLE 403 MEDTRONIC PLC: PRODUCTS OFFERED
TABLE 404 MEDTRONIC PLC: DEALS, JANUARY 2020–JUNE 2024
TABLE 405 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
TABLE 406 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
TABLE 407 ABBOTT LABORATORIES: COMPANY OVERVIEW
TABLE 408 ABBOTT LABORATORIES: PRODUCTS OFFERED
TABLE 409 ABBOTT LABORATORIES: DEALS, JANUARY 2020–JUNE 2024
TABLE 410 MERCK KGAA: COMPANY OVERVIEW
TABLE 411 MERCK KGAA: PRODUCTS OFFERED
TABLE 412 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 413 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
TABLE 414 BICO- THE BIO CONVERGENCE COMPANY: COMPANY OVERVIEW
TABLE 415 BICO - THE BIO CONVERGENCE COMPANY: PRODUCTS OFFERED
TABLE 416 ELUTIA: COMPANY OVERVIEW
TABLE 417 ELUTIA: PRODUCTS OFFERED
TABLE 418 W.L. GORE AND ASSOCIATES, INC.: COMPANY OVERVIEW
TABLE 419 W.L. GORE AND ASSOCIATES, INC.: PRODUCTS OFFERED
TABLE 420 MERIL LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW
TABLE 421 MERIL LIFESCIENCES PVT. LTD.: PRODUCTS OFFERED
TABLE 422 VASCUDYNE, INC.: COMPANY OVERVIEW
TABLE 423 VASCUDYNE, INC.: PRODUCTS OFFERED
TABLE 424 REPROCELL, INC.: COMPANY OVERVIEW
TABLE 425 REPROCELL, INC.: PRODUCTS OFFERED
TABLE 426 REPROCELL: DEALS, JANUARY 2020–JUNE 2024
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 MATERIAL DEFINITION
1.2.2 PRODUCT DEFINITION
1.2.3 APPLICATION DEFINITION
1.2.4 END USER DEFINITION
1.2.5 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 LIMITATIONS
2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.2 RESEARCH METHODOLOGY DESIGN
2.2.1 SECONDARY RESEARCH
2.2.2 KEY DATA FROM SECONDARY SOURCES
2.2.3 PRIMARY DATA
2.2.4 KEY DATA FROM PRIMARY SOURCES
2.2.5 KEY INDUSTRY INSIGHTS
2.3 MARKET SIZE ESTIMATION
2.4 MARKET BREAKDOWN & DATA TRIANGULATION
2.5 MARKET SHARE ESTIMATION
2.6 STUDY ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 RESEARCH LIMITATIONS
2.8.1 METHODOLOGY-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 CARDIAC TISSUE ENGINEERING MARKET OVERVIEW
4.2 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION
4.3 REGIONAL SNAPSHOT OF CARDIAC TISSUE ENGINEERING MARKET (2023)
4.4 GEOGRAPHIC MIX: CARDIAC TISSUE ENGINEERING MARKET,
2024–2029 (USD MILLION)
4.5 CARDIAC TISSUE ENGINEERING MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2029 (USD MILLION)
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of cardiovascular diseases
5.2.1.2 Increase in support from major market players and government bodies
5.2.1.3 Increased demand for regenerative medicine
5.2.1.4 Advancements in 3D bioprinting
5.2.2 RESTRAINTS
5.2.2.1 High cost of treatment
5.2.2.2 Complex regulatory process
5.2.3 OPPORTUNITIES
5.2.3.1 Technological advancements in cardiac tissue engineering
5.2.3.2 Enhanced functionality and integration of cardiac tissues using biomaterials
5.2.3.3 Increase in stem cell research to treat cardiovascular diseases
5.2.4 CHALLENGES
5.2.4.1 Safety concerns and complexity of biomaterials
5.2.4.2 Limited awareness and availability of skilled professionals
5.3 INDUSTRY TRENDS
5.3.1 DEVELOPMENT OF BIOCOMPATIBLE AND BIODEGRADABLE MATERIALS
5.3.2 INTEGRATION OF MICROFLUIDICS AND ELECTRICAL STIMULATION FOR IMPROVED CELL FUNCTION AND TISSUE MATURATION
5.3.3 EXPANSION OF CARDIAC TISSUE ENGINEERING APPLICATIONS
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.2 STEM CELL TECHNOLOGY
5.4.3 3D BIOPRINTING
5.4.4 BIOREACTORS
5.4.5 COMPLEMENTARY TECHNOLOGY
5.4.6 GENE EDITING
5.4.7 ELECTROSPINNING
5.4.8 MICROFLUIDICS
5.4.9 ADJACENT TECHNOLOGIES
5.4.9.1 Biosensors
5.4.10 ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING
5.4.11 NANOTECHNOLOGY
5.5 PIPELINE ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 THREAT OF SUBSTITUTES
5.7.3 BARGAINING POWER OF SUPPLIERS
5.7.4 BARGAINING POWER OF BUYERS
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.8.2 BUYING CRITERIA
5.9 REGULATORY LANDSCAPE
5.9.1 REGULATORY ANALYSIS
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10 PATENT ANALYSIS
5.10.1 PATENT PUBLICATION TRENDS FOR CARDIAC TISSUE ENGINEERING MARKET
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
5.11.2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2021 (USD MILLION)
5.11.3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2021 (USD MILLION)
5.12 PRICING ANALYSIS
5.13 KEY CONFERENCES AND EVENTS, 2024–2025
5.14 UNMET NEEDS IN CARDIAC TISSUE ENGINEERING MARKET
5.15 END USER EXPECTATIONS IN CARDIAC TISSUE ENGINEERING MARKET
5.16 AI INTEGRATION IN CARDIAC TISSUE ENGINEERING MARKET
5.17 ECOSYSTEM ANALYSIS
5.18 CASE STUDIES
5.19 SUPPLY CHAIN ANALYSIS
5.20 CARDIAC TISSUE ENGINEERING MARKET: INVESTMENT AND FUNDING SCENARIO
5.21 ADJACENT MARKET ANALYSIS
5.21.1 TISSUE ENGINEERING MARKET
6 CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL
6.1 INTRODUCTION
6.2 STEM CELLS
6.2.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO DRIVE MARKET
6.3 SCAFFOLDS
6.3.1 SYNTHETIC SCAFFOLDS
6.3.1.1 Advancements in fabrication techniques to drive market
6.3.2 BIOLOGICAL SCAFFOLDS
6.3.3 COLLAGEN-BASED SCAFFOLDS
6.3.3.1 Biocompatibility of material – key driver
6.3.3.2 Hydrogel-based scaffolds
6.3.3.2.1 Low mechanical strength to restrain segment growth
7 CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT
7.1 INTRODUCTION
7.2 VASCULAR GRAFTS
7.2.1 INCREASE IN PREVALENCE OF CORONARY ARTERY DISEASE TO DRIVE MARKET
7.3 CARDIAC PATCHES
7.3.1 INCREASE IN CLINICAL TRIALS FOR CARDIAC PATCHES TO BOOST MARKET
7.4 HEART VALVES
7.4.1 INCREASE IN PREVALENCE OF VALVE REGURGITATION TO DRIVE MARKET
8 CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 MYOCARDIAL INFARCTION
8.2.1 IMPROVED STRUCTURAL INTEGRATION TO DRIVE MARKET GROWTH
8.3 HEART VALVE REPAIR/REPLACEMENT
8.3.1 INCREASE IN INCIDENCE OF AORTIC STENOSIS TO DRIVE MARKET
8.4 CONGENITAL HEART DISEASE
8.4.1 SIGNIFICANT INVESTMENT BY KEY MARKET PLAYERS TO DRIVE MARKET
8.5 OTHER APPLICATIONS
9 CARDIAC TISSUE ENGINEERING MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS & CLINICS
9.2.1 ADVANCED INFRASTRUCTURE AND ACCESS TO CLINICAL TRIALS – KEY DRIVERS
9.3 ACADEMIC & RESEARCH INSTITUTES
9.3.1 AVAILABILITY OF FUNDING FOR RESEARCH – KEY DRIVER
9.4 OTHER END USERS
10 CARDIAC TISSUE ENGINEERING MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 Increasing government grants for research to drive market
10.2.3 CANADA
10.2.3.1 Availability of funding for research on regenerative medicine to fuel market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 UK
10.3.2.1 Fastest-growing market for cardiac tissue engineering in Europe
10.3.3 GERMANY
10.3.3.1 Rising prevalence of cardiovascular diseases – key driver
10.3.4 FRANCE
10.3.4.1 Increasing focus on regenerative medicine to boost market
10.3.5 ITALY
10.3.5.1 Insufficient research funding to restrain growth of market
10.3.6 SPAIN
10.3.6.1 Increase in R&D investment to drive market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 JAPAN
10.4.2.1 Increasing aging population to drive market growth
10.4.3 CHINA
10.4.3.1 Major cardiac tissue engineering market in Asia Pacific
10.4.4 INDIA
10.4.4.1 Increasing government initiatives for clinical trials in stem cell research to boost market
10.4.5 AUSTRALIA
10.4.5.1 Growing government support to fuel market
10.4.6 SOUTH KOREA
10.4.6.1 Advancements in technology and strong government support to drive market growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Increase in prevalence of congenital heart disease to drive market
10.5.3 MEXICO
10.5.3.1 Rapidly growing geriatric population – key driver
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 EXPANDING NETWORK OF ADVANCED HEALTHCARE FACILITIES TO SUPPORT MARKET GROWTH
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.3 GCC COUNTRIES
10.6.3.1 Increased inclination toward novel therapies – key driver
10.6.4 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.3 REVENUE SHARE ANALYSIS
11.4 MARKET SHARE ANALYSIS
11.5 VALUATION AND FINANCIAL METRICS OF HEALTHCARE SERVICE VENDORS
11.6 COMPANY EVALUATION MATRIX, KEY PLAYERS (2023)
11.6.1 STARS
11.6.2 EMERGING LEADERS
11.6.3 PERVASIVE PLAYERS
11.6.4 PARTICIPANTS
11.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.6.5.1 Company footprint
11.6.5.2 Region footprint
11.6.5.3 Application footprint
11.6.5.4 Product footprint
11.6.5.5 Material footprint
11.6.5.6 End user footprint
11.7 COMPANY EVALUATION MATRIX, STARTUPS/SMES (2023)
11.7.1 PROGRESSIVE COMPANIES
11.7.2 RESPONSIVE COMPANIES
11.7.3 DYNAMIC COMPANIES
11.7.4 STARTING BLOCKS
11.7.5 COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
11.7.5.1 Detailed list of key startups/smes
11.7.5.2 Competitive benchmarking of key startups/SMEs
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES
11.8.2 DEALS
11.9 BRAND/PRODUCT COMPARATIVE ANALYSIS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 TERUMO CORPORATION
12.1.1.1 Business overview
12.1.1.2 Products offered
12.1.1.3 MnM view
12.1.1.3.1 Right to win
12.1.1.3.2 Strategic choices
12.1.1.3.3 Weaknesses & competitive threats
12.1.2 ARTIVION, INC.
12.1.2.1 Business overview
12.1.2.2 Products offered
12.1.2.3 Recent developments
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 BAXTER INTERNATIONAL, INC.
12.1.3.1 Business overview
12.1.3.2 Products offered
12.1.3.3 Recent developments
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 TEIJIN LIMITED
12.1.4.1 Business overview
12.1.4.2 Products offered
12.1.4.3 MnM view
12.1.4.3.1 Right to win
12.1.4.3.2 Strategic choices
12.1.4.3.3 Weaknesses & competitive threats
12.1.5 MEDTRONIC PLC
12.1.5.1 Business overview
12.1.5.2 Products offered
12.1.5.3 Recent developments
12.1.5.4 MnM view
12.1.5.4.1 Right to win
12.1.5.4.2 Strategic choices
12.1.5.4.3 Weaknesses & competitive threats
12.1.6 BOSTON SCIENTIFIC CORPORATION
12.1.6.1 Business overview
12.1.6.2 Products offered
12.1.7 ABBOTT LABORATORIES
12.1.7.1 Business overview
12.1.7.2 Products offered
12.1.7.3 Recent developments
12.1.8 MERCK KGAA
12.1.8.1 Business overview
12.1.8.2 Products offered
12.1.9 FUJIFILM HOLDINGS CORPORATION
12.1.9.1 Business overview
12.1.9.2 Products offered
12.1.10 BICO - THE BIO CONVERGENCE COMPANY
12.1.10.1 Business overview
12.1.10.2 Products offered
12.1.11 ELUTIA
12.1.11.1 Business overview
12.1.11.2 Products offered
12.1.12 W. L. GORE AND ASSOCIATES, INC.
12.1.12.1 Business overview
12.1.12.2 Products offered
12.1.13 MERIL LIFESCIENCES PVT. LTD.
12.1.13.1 Business overview
12.1.13.2 Products offered
12.1.14 VASCUDYNE, INC.
12.1.14.1 Business overview
12.1.14.2 Products offered
12.1.15 REPROCELL, INC.
12.1.15.1 Business overview
12.1.15.2 Products offered
12.1.15.3 Recent developments
12.2 OTHER PLAYERS
12.2.1 AXOL BIOSCIENCE LTD.
12.2.2 BPS BIOSCIENCE, INC.
12.2.3 TAKARA BIO, INC.
12.2.4 XELTIS
12.2.5 VISCOFAN DE GMBH
12.2.6 CELL APPLICATION, INC
12.2.7 PROMOCELL GMBH
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
TABLE 1 CURRENCY CONVERSION RATES
TABLE 2 US: LEADING CAUSES OF DEATHS, 2021–2022
TABLE 3 CARDIAC TISSUE ENGINEERING MARKET: R&D PIPELINE
TABLE 4 CARDIAC TISSUE ENGINEERING MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 5 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF
CARDIAC TISSUE ENGINEERING PRODUCTS
TABLE 6 KEY BUYING CRITERIA FOR CARDIAC TISSUE ENGINEERING PRODUCTS
TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS
TABLE 12 CARDIAC TISSUE ENGINEERING MARKET: LIST OF PATENTS, 2014–2024
TABLE 13 AVERAGE SELLING PRICE OF CARDIAC TISSUE ENGINEERING PRODUCTS (USD)
TABLE 14 AVERAGE SELLING PRICE OF KEY CARDIAC TISSUE ENGINEERING PRODUCTS,
BY REGION, 2023 (USD)
TABLE 15 CARDIAC TISSUE ENGINEERING MARKET: KEY CONFERENCES
AND EVENTS, 2024–2025
TABLE 16 CARDIAC TISSUE ENGINEERING MARKET: UNMET NEEDS
TABLE 17 CARDIAC TISSUE ENGINEERING MARKET: END USER EXPECTATIONS
TABLE 18 CARDIAC TISSUE ENGINEERING MARKET: AI INTEGRATION
TABLE 19 CARDIAC TISSUE ENGINEERING MARKET: ECOSYSTEM ANALYSIS
TABLE 20 CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 1
TABLE 21 CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 2
TABLE 22 CARDIAC TISSUE ENGINEERING MARKET: CASE STUDY 3
TABLE 23 CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 24 CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 25 KEY PROVIDERS OF STEM CELLS
TABLE 26 STEM CELLS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 27 STEM CELLS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 28 KEY PROVIDERS OF SCAFFOLDS
TABLE 29 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY TYPE,
2021–2023 (USD MILLION)
TABLE 30 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY TYPE,
2024–2029 (USD MILLION)
TABLE 31 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 32 SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 33 SYNTHETIC SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 34 SYNTHETIC SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 35 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY TYPE, 2021–2023 (USD MILLION)
TABLE 36 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY TYPE, 2024–2029 (USD MILLION)
TABLE 37 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 38 BIOLOGICAL SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 39 COLLAGEN-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 40 COLLAGEN-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 41 HYDROGEL-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 42 HYDROGEL-BASED SCAFFOLDS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 43 CARDIAC TISSUE ENGINEERING MARKET, PIPELINE ANALYSIS
TABLE 44 CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 45 CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 46 VASCULAR GRAFTS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 47 VASCULAR GRAFTS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 48 CARDIAC PATCHES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 49 CARDIAC PATCHES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 50 HEART VALVES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 51 HEART VALVES: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 52 CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 53 CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 54 MYOCARDIAL INFARCTION: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 55 MYOCARDIAL INFARCTION: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 56 HEART VALVE REPAIR/REPLACEMENT: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 57 HEART VALVE REPAIR/REPLACEMENT: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 58 CONGENITAL HEART DISEASE: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 59 CONGENITAL HEART DISEASE: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 60 OTHER APPLICATIONS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2021–2023 (USD MILLION)
TABLE 61 OTHER APPLICATIONS: CARDIAC TISSUE ENGINEERING MARKET,
BY COUNTRY/REGION, 2024–2029 (USD MILLION)
TABLE 62 CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)E
TABLE 63 CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 64 HOSPITALS & CLINICS: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2021–2023 (USD MILLION)
TABLE 65 HOSPITALS & CLINICS: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2024–2029 (USD MILLION)
TABLE 66 ACADEMIC & RESEARCH INSTITUTES: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2021–2023 (USD MILLION)
TABLE 67 ACADEMIC & RESEARCH INSTITUTES: CARDIAC TISSUE ENGINEERING MARKET,
BY REGION, 2024–2029 (USD MILLION)
TABLE 68 OTHER END USERS: CARDIAC TISSUE ENGINEERING MARKET, BY REGION,
2021–2023 (USD MILLION)
TABLE 69 OTHER END USERS: CARDIAC TISSUE ENGINEERING MARKET, BY REGION,
2024–2029 (USD MILLION)
TABLE 70 CARDIAC TISSUE ENGINEERING MARKET, BY REGION, 2021–2023 (USD MILLION)
TABLE 71 CARDIAC TISSUE ENGINEERING MARKET, BY REGION, 2024–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 73 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 75 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 77 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 78 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 79 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 80 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 81 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 82 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 83 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 84 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 85 NORTH AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 86 US: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 87 US: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 88 US: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 89 US: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 90 US: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 91 US: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 92 US: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 93 US: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 94 US: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 95 US: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 96 US: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 97 US: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 98 CANADA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 99 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 100 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 101 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 102 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 103 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 104 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 105 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 106 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 107 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 108 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 109 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 110 CANADA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 111 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 112 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 113 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 114 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 115 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 116 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 117 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 118 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 119 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 120 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 121 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 122 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 123 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 124 EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 125 UK: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 126 UK: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 127 UK: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 128 UK: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 129 UK: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 130 UK: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 131 UK: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 132 UK: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 133 UK: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 134 UK: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 135 UK: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 136 UK: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 137 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 138 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 139 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 140 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 141 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 142 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 143 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 144 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 145 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 146 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 147 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 148 GERMANY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 149 FRANCE: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 150 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 151 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 152 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 153 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 154 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 155 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 156 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 157 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 158 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 159 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 160 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 161 FRANCE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 162 ITALY: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 163 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 164 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 165 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 166 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 167 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 168 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 169 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 170 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 171 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 172 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 173 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 174 ITALY: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 175 SPAIN: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 176 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 177 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 178 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 179 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 180 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 181 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 182 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 183 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 184 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 185 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 186 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 187 SPAIN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 188 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 189 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 190 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 191 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 192 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 193 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 194 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 195 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 196 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 197 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 198 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 199 REST OF EUROPE: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 200 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 201 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 202 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 203 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 205 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 206 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 207 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 208 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 209 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 210 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 211 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 212 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 213 ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 214 JAPAN: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 215 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 216 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 217 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 218 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 219 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 220 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 221 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 222 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 223 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 224 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 225 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 226 JAPAN: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 227 CHINA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 228 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 229 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 230 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 231 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 232 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 233 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 234 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 235 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 236 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 237 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 238 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 239 CHINA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 240 INDIA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 241 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 242 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 243 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 244 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 245 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL TYPE,
2021–2023 (USD MILLION)
TABLE 246 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL TYPE,
2024–2029 (USD MILLION)
TABLE 247 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 248 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 249 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 250 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 251 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 252 INDIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 253 AUSTRALIA: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 254 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 255 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 256 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 257 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 258 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 259 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 260 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 261 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 262 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 263 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 264 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 265 AUSTRALIA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 266 SOUTH KOREA: KEY MACROINDICATORS FOR CARDIAC
TISSUE ENGINEERING MARKET
TABLE 267 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 268 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 269 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 270 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 271 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 272 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 273 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 274 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 275 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 276 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 277 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 278 SOUTH KOREA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 279 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 280 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 281 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 282 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 283 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 284 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 285 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 286 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 287 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 288 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 289 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2021–2023 (USD MILLION)
TABLE 290 REST OF ASIA PACIFIC: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2024–2029 (USD MILLION)
TABLE 291 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2021–2023 (USD MILLION)
TABLE 292 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY,
2024–2029 (USD MILLION)
TABLE 293 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 294 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 295 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 296 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 297 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 298 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 299 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 300 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 301 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 302 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 303 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 304 LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 305 BRAZIL: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 306 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 307 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 308 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 309 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 310 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 311 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 312 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 313 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 314 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION ,
2021–2023 (USD MILLION)
TABLE 315 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 316 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 317 BRAZIL: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 318 MEXICO: KEY MACROINDICATORS FOR CARDIAC TISSUE ENGINEERING MARKET
TABLE 319 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 320 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 321 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2021–2023 (USD MILLION)
TABLE 322 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE,
2024–2029 (USD MILLION)
TABLE 323 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 324 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 325 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 326 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 327 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2021–2023 (USD MILLION)
TABLE 328 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION,
2024–2029 (USD MILLION)
TABLE 329 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 330 MEXICO: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 331 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 332 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 333 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 334 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 335 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 336 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 337 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 338 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 339 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 340 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 341 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2021–2023 (USD MILLION)
TABLE 342 REST OF LATIN AMERICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2024–2029 (USD MILLION)
TABLE 343 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY, 2021–2023 (USD MILLION)
TABLE 344 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY COUNTRY, 2024–2029 (USD MILLION)
TABLE 345 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 346 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 347 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 348 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 349 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 350 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 351 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 352 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 353 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 354 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 355 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2021–2023 (USD MILLION)
TABLE 356 MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET, BY END USER, 2024–2029 (USD MILLION)
TABLE 357 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2021–2023 (USD MILLION)
TABLE 358 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY MATERIAL,
2024–2029 (USD MILLION)
TABLE 359 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 360 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 361 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 362 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 363 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2021–2023 (USD MILLION)
TABLE 364 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY PRODUCT,
2024–2029 (USD MILLION)
TABLE 365 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 366 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 367 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2021–2023 (USD MILLION)
TABLE 368 GCC COUNTRIES: CARDIAC TISSUE ENGINEERING MARKET, BY END USER,
2024–2029 (USD MILLION)
TABLE 369 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY MATERIAL, 2021–2023 (USD MILLION)
TABLE 370 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY MATERIAL, 2024–2029 (USD MILLION)
TABLE 371 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 372 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 373 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY BIOLOGICAL SCAFFOLD TYPE, 2021–2023 (USD MILLION)
TABLE 374 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY BIOLOGICAL SCAFFOLD TYPE, 2024–2029 (USD MILLION)
TABLE 375 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY PRODUCT, 2021–2023 (USD MILLION)
TABLE 376 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY PRODUCT, 2024–2029 (USD MILLION)
TABLE 377 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2021–2023 (USD MILLION)
TABLE 378 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY APPLICATION, 2024–2029 (USD MILLION)
TABLE 379 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2021–2023 (USD MILLION)
TABLE 380 REST OF MIDDLE EAST & AFRICA: CARDIAC TISSUE ENGINEERING MARKET,
BY END USER, 2024–2029 (USD MILLION)
TABLE 381 OVERVIEW OF STRATEGIES DEPLOYED BY CARDIAC TISSUE ENGINEERING
MARKET PLAYERS
TABLE 382 CARDIAC TISSUE ENGINEERING MARKET: DEGREE OF COMPETITION
TABLE 383 CARDIAC TISSUE ENGINEERING MARKET: REGION FOOTPRINT
TABLE 384 CARDIAC TISSUE ENGINEERING MARKET: APPLICATION FOOTPRINT
TABLE 385 CARDIAC TISSUE ENGINEERING MARKET: PRODUCT FOOTPRINT
TABLE 386 CARDIAC TISSUE ENGINEERING MARKET: MATERIAL FOOTPRINT
TABLE 387 CARDIAC TISSUE ENGINEERING: END USER FOOTPRINT
TABLE 388 CARDIAC TISSUE ENGINEERING MARKET: KEY STARTUPS/SMES
TABLE 389 CARDIAC TISSUE ENGINEERING MARKET: COMPETITIVE BENCHMARKING
OF KEY EMERGING PLAYERS/STARTUPS
TABLE 390 CARDIAC TISSUE ENGINEERING MARKET: PRODUCT LAUNCHES,
JANUARY 2020–JUNE 2023
TABLE 391 CARDIAC TISSUE ENGINEERING MARKET: DEALS, JANUARY 2020–JUNE 2024
TABLE 392 TERUMO CORPORATION: COMPANY OVERVIEW
TABLE 393 TERUMO CORPORATION: PRODUCTS OFFERED
TABLE 394 ARTIVION, INC.: COMPANY OVERVIEW
TABLE 395 ARTIVION, INC.: PRODUCTS OFFERED
TABLE 396 ARTIVION, INC.: DEALS, JANUARY 2020–JUNE 2024
TABLE 397 BAXTER INTERNATIONAL, INC: COMPANY OVERVIEW
TABLE 398 BAXTER INTERNATIONAL, INC.: PRODUCTS OFFERED
TABLE 399 BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2020–JUNE 2024
TABLE 400 TEIJIN LIMITED: COMPANY OVERVIEW
TABLE 401 TEIJIN LIMITED: PRODUCTS OFFERED
TABLE 402 MEDTRONIC PLC: COMPANY OVERVIEW
TABLE 403 MEDTRONIC PLC: PRODUCTS OFFERED
TABLE 404 MEDTRONIC PLC: DEALS, JANUARY 2020–JUNE 2024
TABLE 405 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
TABLE 406 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
TABLE 407 ABBOTT LABORATORIES: COMPANY OVERVIEW
TABLE 408 ABBOTT LABORATORIES: PRODUCTS OFFERED
TABLE 409 ABBOTT LABORATORIES: DEALS, JANUARY 2020–JUNE 2024
TABLE 410 MERCK KGAA: COMPANY OVERVIEW
TABLE 411 MERCK KGAA: PRODUCTS OFFERED
TABLE 412 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW
TABLE 413 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED
TABLE 414 BICO- THE BIO CONVERGENCE COMPANY: COMPANY OVERVIEW
TABLE 415 BICO - THE BIO CONVERGENCE COMPANY: PRODUCTS OFFERED
TABLE 416 ELUTIA: COMPANY OVERVIEW
TABLE 417 ELUTIA: PRODUCTS OFFERED
TABLE 418 W.L. GORE AND ASSOCIATES, INC.: COMPANY OVERVIEW
TABLE 419 W.L. GORE AND ASSOCIATES, INC.: PRODUCTS OFFERED
TABLE 420 MERIL LIFESCIENCES PVT. LTD.: COMPANY OVERVIEW
TABLE 421 MERIL LIFESCIENCES PVT. LTD.: PRODUCTS OFFERED
TABLE 422 VASCUDYNE, INC.: COMPANY OVERVIEW
TABLE 423 VASCUDYNE, INC.: PRODUCTS OFFERED
TABLE 424 REPROCELL, INC.: COMPANY OVERVIEW
TABLE 425 REPROCELL, INC.: PRODUCTS OFFERED
TABLE 426 REPROCELL: DEALS, JANUARY 2020–JUNE 2024
